ArticleJournal of food science2025
Canola Protein Hydrolysates Show Osteogenic Activity in MC3T3-E1 Cells.
Article in Journal of food science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Osteoporosis, the most prevalent metabolic bone disorder, is a major public health issue. Previous studies indicated the potential of food components in mitigating the risks of osteoporosis. The study aimed to evaluate the potential of canola protein hydrolysates (CPH) on osteoclastogenesis using a pre-osteoblast cell MC3T3-E1. Twenty-two CPHs were prepared by 12 different proteases, either individually or in combination. Three CPHs, prepared by trypsin (CPH-T), Protex 6L (CPH-P), and the combination of Protex 6L and thermoase (CPH-PT) showed promising activity in promoting in vitro bone formation. CPH-T and CPH-PT improved cell proliferation at a concentration of 10 ug/ml, while all three hydrolysates exhibited cytotoxicity at 1000 ug/ml. All three hydrolysates promoted the level of runt-related transcription factor 2 (RUNX2) and type I collagen, and mineralization in osteoblast cells, in a dose-dependent manner. Additionally, these three hydrolysates elevated the osteoprotegerin (OPG) level and reduced the level of receptor activator of nuclear factor kappa-B ligand (RANKL). This study indicated the activity of CPHs in the promotion of bone formation and prevention of osteoclastogenesis, suggesting the potential of CPHs as a promising functional food ingredient against osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.